EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Detection of Δ 9 ‐tetrahydrocannabinol (THC) in oral fluid using two point‐of‐collection testing devices following oral administration of a THC and cannabidiol containing oil

Anastasia Suraev iD, Danielle McCartney iD, Richard Kevin, Rebecca Gordon, Ronald R Grunstein, Camilla M Hoyos, Iain S McGregor

Drug Testing and Analysis · 2024

DOI: 10.1002/dta.3658 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Testing and Analysis, 2024. Verfasst von Anastasia Suraev und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Dronabinol, Cannabidiol, Substance Abuse Detection, Cross-Over Studies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lambert Initiative for Cannabinoid Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Point‐of‐collection testing (POCT) devices are widely used in roadside and workplace drug testing to identify recent cannabis use by measuring the presence of Δ 9 ‐tetrahydrocannabinol (THC) in oral fluid (OF). However, the performance of POCT devices with oral medicinal cannabis products remains poorly described. In a randomised, double‐blinded, crossover trial, adults with insomnia disorder ( n = 20) received a single (2 mL) oral dose of oil containing 10 mg THC + 200 mg cannabidiol, or placebo, prior to sleep. Participants were tested with the Securetec DrugWipe® 5S (10 ng/mL THC cut‐off) and Dräger DrugTest® 5000 (25 ng/mL THC cut‐off) POCT devices at baseline (pre‐treatment) and then at 0.5, 10, and 18 h post‐treatment. An OF sample, taken at each time point, was also analysed using liquid chromatography–tandem mass spectrometry. Large individual variability in OF THC concentrations was observed 0.5 h post‐treatment (range: 0–425 ng/mL; mean ( SD ) 48.7 (107.5) ng/mL). Both the Securetec DrugWipe® 5S and DrugTest® 5000 demonstrated poor sensitivity to THC at 0.5 h post‐treatment (25% and 50%, respectively). At 10 and 18 h post‐treatment, all participant OF THC concentrations were below screening cut‐offs, and all test results were negative. These findings highlight the relatively poor sensitivity of both devices in detecting recent use of an oral medicinal cannabis product. They also suggest a low probability of obtaining a positive THC result the morning after (‘one‐off’) use. Further research is required to establish the probability of obtaining a positive THC result with regular medicinal cannabis use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DronabinolCannabidiolSubstance Abuse DetectionCross-Over StudiesSalivaHumansAdultDouble-Blind MethodMaleAdministration, OralFemaleMiddle AgedTandem Mass SpectrometryYoung AdultSleep Initiation and Maintenance DisordersChromatography, LiquidMedical Marijuana

Stichwörter der Autor:innen

THCcannabisdrug testingoral fluidpoint‐of‐collection testing

Substanzen

DronabinolCannabidiolMedical Marijuana

Autor:innen und Institutionen

  • Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.
  • Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia.
  • School of Psychology, Faculty of Science, University of Sydney, Sydney, New South Wales, Australia.
  • Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
  • St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.

ORCID-Profile: Anastasia Suraev, Danielle McCartney

Förderung

  • Lambert Initiative for Cannabinoid Therapeutics

Zitieren

APA

Suraev, A., McCartney, D., Kevin, R., Gordon, R., Grunstein, R. R., Hoyos, C. M., & McGregor, I. S. (2024). Detection of Δ 9 ‐tetrahydrocannabinol (THC) in oral fluid using two point‐of‐collection testing devices following oral administration of a THC and cannabidiol containing oil. Drug Testing and Analysis. https://doi.org/10.1002/dta.3658

Vancouver

Suraev A, McCartney D, Kevin R, Gordon R, Grunstein RR, Hoyos CM, et al. Detection of Δ 9 ‐tetrahydrocannabinol (THC) in oral fluid using two point‐of‐collection testing devices following oral administration of a THC and cannabidiol containing oil. Drug Testing and Analysis. 2024. doi:10.1002/dta.3658

BibTeX
@article{Suraev2024,
  author = {Suraev, Anastasia and McCartney, Danielle and Kevin, Richard and Gordon, Rebecca and Grunstein, Ronald R and Hoyos, Camilla M and McGregor, Iain S},
  title = {Detection of Δ 9 ‐tetrahydrocannabinol (THC) in oral fluid using two point‐of‐collection testing devices following oral administration of a THC and cannabidiol containing oil},
  journal = {Drug Testing and Analysis},
  year = {2024},
  doi = {10.1002/dta.3658}
}
Kostenlos starten →